Analisis Faktor yang Berhubungan dengan Potensi Interaksi Obat Pasien Covid-19 di Salah Satu Rumah Sakit Kalimantan Selatan

Factors Associated with Potential Drug Interactions in Covid-19 Hospitalized Patients

Authors

  • Okta Muthia Sari Program Studi Farmasi Fakultas Matematika dan Ilmu Pengetahuan Alam, Universitas Lambung Mangkurat, Indonesia Author
  • Aditya Maulana Perdana Putra Program Studi Farmasi Fakultas Matematika dan Ilmu Pengetahuan Alam, Universitas Lambung Mangkurat, Indonesia Author
  • Yusrinie Wasiaturrahmah Program Studi Kedokteran Gigi, Fakultas Kedokteran Gigi, Universitas Lambung Mangkurat, Indonesia Author
  • Nahdiya Rahmah Program Studi Farmasi Fakultas Matematika dan Ilmu Pengetahuan Alam, Universitas Lambung Mangkurat, Indonesia Author

DOI:

https://doi.org/10.30872/jsk.v5i5.441

Keywords:

COVID-19, faktor berhubungan, interaksi obat, potensi

Abstract

Tatalaksana pengobatan pada pasien COVID-19 diberikan antivirus, terapi suportif dan terapi simptomatik. Penggunaan beberapa jenis obat tersebut membuat pasien COVID-19 berpotensi mengalami interaksi obat. Penelitian ini bertujuan menganalisis faktor yang berhubungan dengan potensi interaksi obat pada pasien COVID-19 rawat inap di rumah sakit. Penelitian obeservasional retrospektif cross sectional ini dilaksanakan di salah satu rumah sakit Kalimantan Selatan. Sampel yakni rekam medis pasien COVID-19 yang mendapat terapi dan rawat inap di rumah sakit periode Januari-Maret 2021 Instrumen penelitian mengkaji potensi dan mekanisme interaksi obat meliputi situs IBM Micromedex , DrugBank Interaction Checker dan Stockley Drug Interactions 9th Edition. Hasil diperoleh sebanyak 82 rekam medis dianalisis potensi interaksi obat. Persentase pasien mengalami potensi interaksi obat sebesar 69,5%. pada pasien COVID-19 rawat inap di rumah sakit. Mekanisme interaksi obat pada pada pasien COVID-19 pada berpotensi pada fase farmakokinetika. Faktor berhubungan potensi interaksi obat pasien COVID-19 yakni usia (p=0.034; OR 0.327, CI 0.11-0.94), jumlah obat yang digunakan selama dirawat (p=0.002; OR 14.00, CI 1.76-111.11) dan lama dirawat (p=0.000; OR 0.009 , CI 0.001-0.07). Kesimpulan, faktor berhubungan potensi interaksi obat pada pasien COVID-19 rawat inap di rumah sakit meliputi usia, jumlah obat yang digunakan selama dirawat dan lama dirawat.

References

N. Afrianti and C. Rahmiati, 2021, Faktor-Faktor yang Mempengaruhi Kepatuhan Masyarakat terhadap Protokol Kesehatan Covid-19, Jurnal Ilmiah Permas: Jurnal Ilmiah STIKES Kendal, vol. 11, no. 1, doi: 10.32583/pskm.v11i1.1045.

P. K. Manjhi, R. Kumar, A. Priya, and I. Rab, 2021, Drug-Drug Interactions in Patients with COVID-19: A Retrospective Study at a Tertiary Care Hospital in Eastern India, Maedica (Bucur), vol. 16, no. 2, pp. 163–169, doi: 10.26574/maedica.2021.16.2.163.

Y. S. Malik et al., 2020, Coronavirus Disease Pandemic (COVID-19): Challenges and a Global Perspective,” Pathogens, vol. 9, no. 7, p. 519, doi: 10.3390/pathogens9070519.

WHO, 2021, WHO Coronavirus Disease (COVID-19) Dashboard, https://covid19.who.int/

E. Mathieu et al., 2023,Coronavirus Pandemic (COVID-19), Our World in Data, 2020, Accessed: Jan. 11, https://ourworldindata.org/coronavirus

Z.-M. Chen et al., 2020, Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus, World J Pediatr, vol. 16, no. 3, pp. 240–246, doi: 10.1007/s12519-020-00345-5.

C. Stasi, S. Fallani, F. Voller, and C. Silvestri, 2020, Treatment for COVID-19: An overview, Eur J Pharmacol, vol. 889, p. 173644, doi: 10.1016/j.ejphar.2020.173644.

E. Burhan et al., 2020, Pedoman Tatalaksana COVID-19 Edisi Ke-3. Jakarta: PDPI, PERKI, PAPDI, PERDATIN & IDAI.

L. A. Kusumawardani, N. Maria, and Y. N. Fanani, 2021,Potential drug interactions analysis of COVID-19 patients at a hospital in West Java, JIF, vol. 17, doi: 10.20885/jif.vol17.iss2.art8.

A. Anggriani, P. Utami, and I. Lisni, 2016, Kajian Potensi Interaksi Obat Pada Pasien Glaukoma di Salah Satu Rumah Sakit di Bandung, Jurnal Sains dan Kesehatan (J. Sains Kes.), vol. 1, no. 5, doi: 10.25026/jsk.v1i5.44.

V. Conti et al., 2022, Identification of Drug Interaction Adverse Events in Patients With COVID-19: A Systematic Review, JAMA Network Open, vol. 5, no. 4, p. e227970, Apr. doi: 10.1001/jamanetworkopen.2022.7970.

D. Kumar and N. Trivedi, 2021, Disease-drug and drug-drug interaction in COVID-19: Risk and assessment, Biomedicine & Pharmacotherapy, vol. 139, p. 111642, doi: 10.1016/j.biopha.2021.111642.

S. S. Maulidia, F. Mahmudah, and Y. Sastyarina, 2021,Kajian Potensi Interaksi Obat pada Pasien COVID-19 di Rumah Sakit X Kota Samarinda: Study of Potential Drug Interactions in COVID-19 Patients at Hospital X Samarinda City, Proceeding of Mulawarman Pharmaceuticals Conferences (Proc. Mul. Pharm. Conf.), vol. 14, pp. 295–301, doi: 10.25026/mpc.v14i1.587.

A. M. P. Putra, Y. Wasiaturrahmah, and N. Rahmah, 2021, Potensi Interaksi Obat Pada Pasien COVID-19 Di Salah Satu Rumah Sakit Di Provinsi Kalimantan Selatan, Majalah Farmasi dan Farmakologi, vol. 25, no. 3, pp. 94–97.

W. Ayenew, G. Asmamaw, and A. Issa, 2020, Prevalence of potential drug-drug interactions and associated factors among outpatients and inpatients in Ethiopian hospitals: a systematic review and meta-analysis of observational studies, BMC Pharmacology and Toxicology, vol. 21, no. 1, p. 63, doi: 10.1186/s40360-020-00441-2.

M.-L. Yeh, Y.-J. Chang, P.-Y. Wang, Y.-C. J. Li, and C.-Y. Hsu, 2013, Physicians’ responses to computerized drug-drug interaction alerts for outpatients, Comput Methods Programs Biomed, vol. 111, no. 1, pp. 17–25, doi: 10.1016/j.cmpb.2013.02.006.

S. Niu et al., 2020, Clinical characteristics of older patients infected with COVID-19: A descriptive study, Archives of Gerontology and Geriatrics, vol. 89, no. April, p. 104058, doi: 10.1016/j.archger.2020.104058.

J. She, L. Liu, and W. Liu, 2020, 2020 COVID?19 epidemic Disease characteristics in children, pp. 747–754.

P. Yu, J. Zhu, Z. Zhang, and Y. Han, 2020, A familial cluster of infection associated with the 2019 novel coronavirus indicating possible person-to-person transmission during the incubation period, Journal of Infectious Diseases, vol. 221, no. 11, pp. 1757–1761, doi: 10.1093/infdis/jiaa077.

B. D. Pepitasari and T. D. Anggraini, 2021, Gambaran Tatalaksana Terapi Pada Pasien COVID-19 Terkonfirmasi di Rumah Sakit X Kota Surakarta Periode Maret – Desember 2020, Journal On Medical Science, vol. 8, no. 2, pp. 119–126.

J. M. Jin et al., 2020,Gender Differences in Patients With COVID-19: Focus on Severity and Mortality, Frontiers in Public Health, vol. 8, no. April, pp. 1–6, doi: 10.3389/fpubh.2020.00152.

R. McQueenie et al., 2020,Multimorbidity, polypharmacy, and COVID-19 infection within the UK Biobank cohort, PLoS ONE, vol. 15, no. 8 August, pp. 1–15, doi: 10.1371/journal.pone.0238091.

R. Chaliks, 2015,Factors Influence the Potential Drug Interaction Occurence among Hospitalized Patients with Cronic Kidney Disease at Labuang Baji Hospital Makassar, International Journal of Sciences: Basic and Applied Research (IJSBAR), vol. 24, no. 3.

I. Cascorbi, 2012, Arzneimittelinteraktionen: Prinzipien, Beispiele und klinische Folgen, Deutsches Arzteblatt International, vol. 109, no. 33–34, pp. 546–556, doi: 10.3238/arztebl.2012.0546.

K. Baxter, 2010, Stockley’s Drug Interactions, Ninth Edition, Pharmaceutical Press, London.

Rikomah, 2018, Farmasi Klinik, Deepublish Publisher, Yogyakarta.

Rodrigues, 2008, Drug-Drug Interaction Second Edition. Informa Healthcare USA.

Micromedex, 2021,“IBM Micromedex, https://www.micromedexsolutions.com/micromedex2/librarian/

C. Tanaka, 2014, Clinical pharmacology of deferasirox, Clinical Pharmacokinetics, vol. 53, no. 8, pp. 679–694, doi: 10.1007/s40262-014-0151-4.

Drugbank, 2022, Drug Interaction Checker, Drug Interaction Checker, https://go.drugbank.com/drug-interaction-checker

D. Sola et al., 2015, Sulfonylureas and their use in clinical practice, Archives of Medical Science, vol. 11, no. 4, pp. 840–848, doi: 10.5114/aoms.2015.53304.

M. May and C. Schindler, 2016, Clinically and pharmacologically relevant interactions of antidiabetic drugs, Therapeutic Advances in Endocrinology and Metabolism, vol. 7, no. 2, pp. 69–83, doi: 10.1177/2042018816638050.

D. R. Morales, J. Slattery, A. Pacurariu, L. Pinheiro, P. McGettigan, and X. Kurz, 2019, Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case–Control Study, Clinical Drug Investigation, vol. 39, no. 2, pp. 205–213, doi: 10.1007/s40261-018-0729-y.

N. Diksis, T. Melaku, D. Assefa, and A. Tesfaye, 2019,Potential drug–drug interactions and associated factors among hospitalized cardiac patients at Jimma University Medical Center, Southwest Ethiopia, SAGE Open Med, vol. 7, p. 2050312119857353, Jun. doi: 10.1177/2050312119857353.

L. Bjerrum, B. Gonzalez Lopez-Valcarcel, and G. Petersen, 2008, Risk factors for potential drug interactions in general practice, European Journal of General Practice, vol. 14, no. 1, pp. 23–29, doi: 10.1080/13814780701815116.

L. Parulian, E. Listyanti, A. K. Hati, and I. Sunnah, 2019, Analisis Hubungan Polifarmasi Dan Interaksi Obat Pada Pasien Rawat Jalan Yang Mendapat Obat Hipertensi Di Rsp. Dr. Ario Wirawan Periode Januari-Maret 2019, Indonesian Journal of Pharmacy and Natural Product, vol. 2, no. 2.

Downloads

Published

2024-11-15

Issue

Vol. 5 No. 5 (2023): J. Sains Kes.

Section

Articles

How to Cite

[1]
O. M. . Sari, A. M. P. . Putra, Y. . Wasiaturrahmah, and N. . Rahmah, “Analisis Faktor yang Berhubungan dengan Potensi Interaksi Obat Pasien Covid-19 di Salah Satu Rumah Sakit Kalimantan Selatan: Factors Associated with Potential Drug Interactions in Covid-19 Hospitalized Patients”, J. Sains. Kes, vol. 5, no. 5, pp. 559–567, Nov. 2024, doi: 10.30872/jsk.v5i5.441.

Similar Articles

171-180 of 283

You may also start an advanced similarity search for this article.